These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 34860120)
1. Repository corticotropin injection improves quality metrics in an observational study of multiple sclerosis relapse. Kaplan J; Miller T; Baker M; Due B; Zhao E Neurodegener Dis Manag; 2021 Dec; 11(6):469-476. PubMed ID: 34860120 [TBL] [Abstract][Full Text] [Related]
2. A Prospective Observational Registry of Repository Corticotropin Injection (Acthar® Gel) for the Treatment of Multiple Sclerosis Relapse. Kaplan J; Miller T; Baker M; Due B; Zhao E Front Neurol; 2020; 11():598496. PubMed ID: 33414758 [No Abstract] [Full Text] [Related]
3. Results from a multicenter, randomized, double-blind, placebo-controlled study of repository corticotropin injection for multiple sclerosis relapse that did not adequately respond to corticosteroids. Wynn D; Goldstick L; Bauer W; Zhao E; Tarau E; Cohen JA; Robertson D; Miller A CNS Neurosci Ther; 2022 Mar; 28(3):364-371. PubMed ID: 34984839 [TBL] [Abstract][Full Text] [Related]
4. Consequences of Insurance Denials Among U.S. Patients Prescribed Repository Corticotropin Injection for Acute Exacerbations of Multiple Sclerosis. Rice JB; Panaccio MP; White A; Simes M; Billmyer E; Downes N; Niewoehner J; Wan GJ Neurol Ther; 2021 Jun; 10(1):149-167. PubMed ID: 33170434 [TBL] [Abstract][Full Text] [Related]
5. Clinical and Economic Evaluation of Repository Corticotropin Injection: A Narrative Literature Review of Treatment Efficacy and Healthcare Resource Utilization for Seven Key Indications. Philbin M; Niewoehner J; Wan GJ Adv Ther; 2017 Aug; 34(8):1775-1790. PubMed ID: 28660550 [TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness of Repository Corticotropin Injection for the Treatment of Acute Exacerbations in Multiple Sclerosis. Hunter SF; Bindra J; Chopra I; Niewoehner J; Panaccio MP; Wan GJ Clinicoecon Outcomes Res; 2021; 13():883-892. PubMed ID: 34675568 [TBL] [Abstract][Full Text] [Related]
7. Results From a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Repository Corticotropin Injection for the Treatment of Pulmonary Sarcoidosis. Mirsaeidi M; Baughman RP; Sahoo D; Tarau E Pulm Ther; 2023 Jun; 9(2):237-253. PubMed ID: 37072607 [TBL] [Abstract][Full Text] [Related]
8. Healthcare Costs and Resource Utilization in Patients with Multiple Sclerosis Relapses Treated with H.P. Acthar Gel(®). Gold LS; Suh K; Schepman PB; Damal K; Hansen RN Adv Ther; 2016 Aug; 33(8):1279-92. PubMed ID: 27312977 [TBL] [Abstract][Full Text] [Related]
9. Comorbidity in multiple sclerosis: Emphasis on patient-reported outcomes. Diržiuvienė B; Mickevičienė D Mult Scler Relat Disord; 2022 Mar; 59():103558. PubMed ID: 35123292 [TBL] [Abstract][Full Text] [Related]
10. Treatment Effectiveness for Resolution of Multiple Sclerosis Relapse in a US Health Plan Population. Nazareth T; Datar M; Yu TC Neurol Ther; 2019 Dec; 8(2):383-395. PubMed ID: 31564036 [TBL] [Abstract][Full Text] [Related]
11. Clinical experience with repository corticotropin injection in patients with multiple sclerosis experiencing mood changes with intravenous methylprednisolone: a case series. Murray S; Woo A Ther Adv Neurol Disord; 2016 May; 9(3):189-97. PubMed ID: 27134674 [TBL] [Abstract][Full Text] [Related]
12. H.P. Acthar Gel (repository corticotropin injection) treatment of patients with multiple sclerosis and diabetes. Kutz C Ther Adv Chronic Dis; 2016 Jul; 7(4):190-7. PubMed ID: 27433309 [TBL] [Abstract][Full Text] [Related]
13. Patient-Reported Outcomes from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar Askanase AD; Wan GJ; Panaccio MP; Zhao E; Zhu J; Bilyk R; Furie RA Rheumatol Ther; 2021 Mar; 8(1):573-584. PubMed ID: 33687687 [TBL] [Abstract][Full Text] [Related]
14. Pain and Fatigue Improvements in Patients Treated with Repository Corticotropin Injection Across Five Indications: A Narrative Review. Girman C; Panaccio MP; Hayes K; Niewoehner J; Wan GJ Adv Ther; 2022 Jul; 39(7):3072-3087. PubMed ID: 35635646 [TBL] [Abstract][Full Text] [Related]
15. Cost per response analysis of repository corticotropin injection Wan GJ; Chopra I; Niewoehner J; Hunter SF Drugs Context; 2020; 9():. PubMed ID: 33408750 [TBL] [Abstract][Full Text] [Related]
16. Impact of multiple sclerosis relapse: The NARCOMS participant perspective. Nickerson M; Cofield SS; Tyry T; Salter AR; Cutter GR; Marrie RA Mult Scler Relat Disord; 2015 May; 4(3):234-40. PubMed ID: 26008940 [TBL] [Abstract][Full Text] [Related]
17. Acthar Gel (RCI): A Narrative Literature Review of Clinical and Economic Evidence. Wan GJ; Niewoehner J; Hayes K Clinicoecon Outcomes Res; 2023; 15():499-512. PubMed ID: 37397803 [TBL] [Abstract][Full Text] [Related]
18. Mitoxantrone: a review of its use in multiple sclerosis. Scott LJ; Figgitt DP CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110 [TBL] [Abstract][Full Text] [Related]